Synkrino Development Company

Over the past year I have been working with a team of career drug developers, experts in life science finance and AI to build Synkrino Development Company, or SDC (https://synkrino.dev). Briefly, SDC sources, licenses and develops multiple portfolios of orthogonal, novel therapeutics programs to achieve major clinical and commercial inflection points. SDC fills a major white space in the drug development landscape. https://lnkd.in/e_9kEfwy As a drug development company, central to its operations is a sophisticated, deep scientific and business diligence process. As Chief Scientific Officer, I run the POP (Pipeline Oversight Panel) our in-depth, AI guided and efficient diligence process, utilizing experts from our network of advisors. To achieve this, we built a robust scientific and business case diligence process for the opportunities in our intake funnel. We have screened hundreds of opportunities. We extensively diligence the science with our Portfolio Oversight Panel (POP) review panel, which includes a network of pharma executives, deep subject matter experts and life science investors. The scientific rationale and ability to differentiate as well as clinical optionality are critical aspects of the review. For those opportunities that the SDC leadership decide to progress based on analysis from the POP and our AI systems, a detailed milestone plan with costs is developed through Phase I human clinical trials in collaboration with the asset owners. Assets that succeed in our POP process are then restructured into milestone driven development plans, before a final review by our Development Committee (or DC), a distinct group of career drug developers, tasked to assess market and clinical path. The POP, milestone and DC process has been applied to dozens of programs, resulting in a highly select portfolio of 20 assets in our first pipeline. Please reach out to us to learn more and visit us at https://synkrino.dev.

SDC was built to take a stage-gated approach to development of early to mid-stage high impact, novel assets through Phase I - where they hit their first clinical and commercial inflection point. Traditional approaches to biotech investment are needlessly volatile, leading to lost opportunities, lost capital - time we cannot recover - for founders, investors and yes, patients. Money floods into Phase II assets, yet is scarce for programs seeking to reach that stage. This strategy isn't just looking for unicorns, this is expecting Athena to burst fully armored and trained from Zeus' head. It just doesn't happen - by failing to appropriately manage the risk inherent to early stage therapeutics, instead large amounts of capital are mis-allocated, huge market opportunities are missed, and patients (you, us, our families) suffer. SDC has a broad approach - to all indications, and all modalities - not just rare or genetically conferred diseases. This broadening opens up oncology, cardiometabolic disease, immunity and inflammation - and yes rare and genetic diseases as well. By moving into a broader clinical and market space #SDC built the most robust and powerful model in drug development and financing today. SDC is not a bridge to the past - it is a village, a community, bringing us into the future, with a new set of powerful, effective therapeutics - for all of us. Acknowledgements to Frank Alzaga-Chaudhry, Francisco Dopazo, Simon Haydar and Michael Sierra for working to launch SDC. Check us out. #SDC #drugdevelopment

Why do we need an alternative approach - like Synkrino Development Company - for the financing and development of therapeutics in the U.S.? Doesn’t biotech VC work fine? Let’s talk about Allakos Inc a biotech that raised $400M plus, including an IPO, and in effect is now losing their ability to move forward on any program due to the poor results on a single asset, an anti-Siglec6, which just failed in trials. Allakos raised $438M dollars over a decade, went public at $150 per share, and now trades at $0.23. Is that capital efficient? Is that smart risk management? Allakos had disappointing results for its urticaria trial - a form of spontaneous hives, an inflammatory condition. This single asset driven result forces the shut down of the company. All that time, money, IP (including its anti Siglec-8) and brainpower wiped out. Single roll of the dice. There is a better way, a capital efficient, risk stage gated approach known as direct to asset financing and development, which Synkrino Development Company is pioneering. Why live with the volatility of current approaches in biotech financing? Why be forced to roll a hard six - bet it all on one program - when you have a full deck of assets? Whether you are an investor, a strategic partner, a pharma BD team, or an entrepreneur with a world class therapeutic program - please reach out to the SDC founding team Frank Alzaga-Chaudhry, Michael Sierra or myself to learn more. SDC has a powerful and promising pipeline of assets in hand for development, and we continue to grow. Come join us. #SDC

What is SDC? SDC is a high efficiency, risk managed 'Direct-to-Asset' based financing and development of therapeutics. SDC is a new risk stage-gated, expert-guidance based approach to drug development. Reach out to learn more, please DM SDC co-founder Frank Alzaga-Chaudhry, Michael Sierra or Jason Barbour. #SDC #JPM #drugdevelopment

Frank Alzaga-Chaudhry, Co-Founder of SDC, and I will be at #JPM SF this week. Please see our presentations on Tuesday and Wednesday at the #IVYFON event - online or in-person. If you are an entrepreneur with an intriguing Lead/DC, CMC or Phase I stage asset, or a strategic or financial partner intrigued by the power of the #SDC model, please reach out to Frank or I directly to learn more.

Others have commented on this recent post from David Li, at Meliora, and I'll add my two cents here, and talk about SDC (synkrino.dev), a new drug development company designed for efficiency and speed. The recent high profile concerns over IP transfer to WuXi, and other Chinese CROs and Pharmas obscures a fundamental point. The Chinese biotech and pharma ecosystem is rapidly out scaling that of the U.S. Refusing to work with WuXi is roughly the equivalent of putting our hands over our ears, and refusing to see the truth - that Chinese companies can compete or out-compete any individual U.S. start-up or biopharma entity on any single given target. David discusses these points in some detail in his post on X, linked below. My take is that the way we manage drug development in the U.S. is capital and time inefficient, and poorly manages risk. We place large amounts of capital into slow moving individual start-ups, and judge their success by IPOs or transactions, not successfully completed clinical trials. Not true products. We built SDC (synkrino.dev) as an asset-centric approach in order to bring world class execution on drug development alongside a genuine sense of urgency and speed. To shut down failing programs fast, and re-direct capital to the best, emergent new therapeutics - and bring to clinical trials and to patients. David is right - the world will not wait for us and the U.S. to find new efficiencies in drug development. The world can and will leapfrog us. We need to re-imagine how we finance and develop therapeutics in this country, and find a way to be better, faster, cheaper - and yes smarter. That is why we built SDC. #SDC #JPM #drugdevelopment #assetcentric #therapeutics David's post on X -> https://lnkd.in/g2-eSWrh

Congratulations to the founding team - Michael Sierra, Frank Alzaga-Chaudhry and Francisco Dopazo - of Synkrino Development Company (SDC) in announcing the first 6 therapeutic assets in its development pipeline. https://lnkd.in/gdKxkx2d These 6 novel, high-ceiling assets span gene therapies to antibodies, peptides to LNPs, small molecules to mRNA, targeting diseases both rare and common, ranging from cardiometabolic disease to oncology to chronic inflammation. These assets represent SDC's approach - the creation of orthogonal baskets of highly promising therapeutic programs poised to achieve major clinical and commercial inflection points. Continually diligencing new programs, the SDC pipeline continues to grow. Synkrino Development Company's expert, AI supported diligence process continually identifies novel therapeutic assets (biological target, disease indication, modality) for development, and de-risk biotech investments for institutional investors and pharma partners. https://lnkd.in/gmRunmUr SDC partners with biotech companies, and academic medical groups, on an asset basis – not a company basis – allowing SDC to provide direct drug development and financial support for the most promising therapeutic programs in the ecosystem. This unparalleled efficiency allows SDC to rapidly move the the most promising programs directly into Phase I trials, and to major value inflection points. Led by CSO, Michael Sierra, the SDC team has more than 100 years in applied drug development experience, and has brought multiple therapeutic programs through trials and into the clinic. SDC has an extensive network of career drug hunters and developers. Francisco Dopazo and Frank Alzaga-Chaudhry bring decades of experience and accomplishments in life science finance, VC, corporate strategic financing, and life science operations. Please reach out to learn more. #drugdevelopment #SDC #finance #innovation #therapeutics #valueinflection

Congratulations to the founding team - Michael Sierra, Frank Alzaga-Chaudhry and Francisco Dopazo - of Synkrino Development Company (SDC) in announcing the first 6 therapeutic assets in its development pipeline. https://lnkd.in/gdKxkx2d These 6 novel, high-ceiling assets span gene therapies to antibodies, peptides to LNPs, small molecules to mRNA, targeting diseases both rare and common, ranging from cardiometabolic disease to oncology to chronic inflammation. These assets represent SDC's approach - the creation of orthogonal baskets of highly promising therapeutic programs poised to achieve major clinical and commercial inflection points. Continually diligencing new programs, the SDC pipeline continues to grow. Synkrino Development Company's expert, AI supported diligence process continually identifies novel therapeutic assets (biological target, disease indication, modality) for development, and de-risk biotech investments for institutional investors and pharma partners. https://lnkd.in/gmRunmUr SDC partners with biotech companies, and academic medical groups, on an asset basis – not a company basis – allowing SDC to provide direct drug development and financial support for the most promising therapeutic programs in the ecosystem. This unparalleled efficiency allows SDC to rapidly move the the most promising programs directly into Phase I trials, and to major value inflection points. Led by CSO, Michael Sierra, the SDC team has more than 100 years in applied drug development experience, and has brought multiple therapeutic programs through trials and into the clinic. SDC has an extensive network of career drug hunters and developers. Francisco Dopazo and Frank Alzaga-Chaudhry bring decades of experience and accomplishments in life science finance, VC, corporate strategic financing, and life science operations. Please reach out to learn more. #drugdevelopment #SDC #finance #innovation #therapeutics #valueinflection

AI and LLMs are impacting every element of the drug discovery and development process - to now include how we select and finance therapeutics to the clinic. SDC draws on raw clinical and market transaction data (not processed reports from providers), and our rigorous primary diligence process. SDC detected unseen trends in pre-clinical and clinical success, as well as financial exits around those assets. What we discovered astonished us - revealing a true open, white-space in therapeutics investment. This work by SDC drove our new approach to selection, development and financing of early to mid-stage therapeutics. Please look us up at the #IVYFON event today in San Diego at #BIO2024. More here on how SDC leverages AI https://lnkd.in/gCgT2jhm #familyoffice #ivyfon #therapeutics #AI #SDC

SDC's Founder Jason Barbour will be talking about the impact of AI and LLMs on not only drug discovery, but the profound impact of AI on how SDC (https://synkrino.dev/) is improving how we select, diligence and finance new therapeutics programs to the clinic. Please join us for the discussion in person or online. #IVYFON #SynkrinoDevelopment #AI #Investing #Therapeutics #FamilyOffice https://lnkd.in/g5gB6c-f